Spondyloarthritis & psoriatic arthritis
The risk of cardiovascular events following treatment for PsA with a biological agent
Main finding · MACEResult — go to the resultHazard ratio 0.65 95% CI 0.43–0.96Authors' conclusion
bDMARDs may reduce cardiovascular events and mortality in PsA, but infection risks warrant close monitoring.
Study context
- Population
- Patients with PsA who had used at least one DMARD, Chang Gung Memorial Research Database, Taiwan, 2001–2022
- Participants
- 2,383 patients
- Exposure
- bDMARDs vs conventional DMARDs
- bDMARDsn = 1,190
- cDMARDsn = 1,193reference
- Outcome
- Major adverse cardiovascular event (MACE), including stroke, MI, cardiovascular mortality or coronary revascularization
Methodological detailsinverse probability of treatment weighting
- Inverse probability of treatment weighting
Main finding
MACE
Hazard ratio
0.65
95% CI 0.43–0.96
By group
bDMARDsvs cDMARDs
HR 0.65 (95% CI 0.43–0.96)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Per 100 person-years
| Outcome | bDMARDs | cDMARDs | HR (95% CI) | |
|---|---|---|---|---|
| All-cause mortality | 0.73 | 1.86 | 0.44 (0.35–0.57) | |
| Cardiovascular mortality | 0.54 (0.32–0.92) | |||
| 0.20.5125Hazard ratio (log scale) |
Safety
| Outcome | Subdistribution HR (95% CI) | |
|---|---|---|
| Infection-related admission | 1.45 (1.18–1.78) | |
| 0.512Subdistribution hazard ratio (log scale) |
Original publication
The risk of cardiovascular events following treatment for PsA with a biological agent. Rheumatology (Oxford). Published 13 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →